AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) has earned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.

Brokerages have set a 1-year consensus price objective of $3.00 for the company and are predicting that the company will post ($0.25) earnings per share for the current quarter, according to Zacks. Zacks has also assigned AEterna Zentaris an industry rank of 103 out of 255 based on the ratings given to its competitors.

Several equities analysts have recently weighed in on the company. TheStreet upgraded AEterna Zentaris from an “e+” rating to a “c” rating in a report on Monday, June 11th. ValuEngine downgraded AEterna Zentaris from a “buy” rating to a “hold” rating in a report on Friday, June 1st. HC Wainwright restated a “buy” rating and set a $3.00 price target on shares of AEterna Zentaris in a report on Wednesday, May 9th. Maxim Group restated a “buy” rating on shares of AEterna Zentaris in a report on Friday, June 15th. Finally, Zacks Investment Research downgraded AEterna Zentaris from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 30th.

AEterna Zentaris stock traded down $0.03 on Friday, hitting $1.82. 59,700 shares of the stock traded hands, compared to its average volume of 269,502. AEterna Zentaris has a 1 year low of $1.12 and a 1 year high of $3.25. The firm has a market capitalization of $31.89 million, a P/E ratio of -1.36 and a beta of 1.14.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last issued its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.16. AEterna Zentaris had a return on equity of 20.71% and a net margin of 6.76%. The firm had revenue of $0.17 million during the quarter. equities analysts expect that AEterna Zentaris will post 0.05 EPS for the current year.

AEterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

See Also: Book Value Of Equity Per Share – BVPS Explained

Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with's FREE daily email newsletter.